MoonLake Immunotherapeutics (MLTX) Liabilities and Shareholders Equity (2020 - 2026)

MoonLake Immunotherapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $400.4 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 21.69% year-over-year to $400.4 million in Q1 2026; TTM through Mar 2026 was $1.7 billion, a 17.2% decrease from a year earlier, with the FY2025 full-year figure at $424.4 million, down 11.19% from the prior year.
• Liabilities and Shareholders Equity fell to $400.4 million in Q1 2026 per MLTX's latest filing, from $424.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $564.1 million in Q1 2024 and bottomed at $66.8 million in Q1 2023.
• The 5-year median for Liabilities and Shareholders Equity is $460.1 million (2025), against an average of $377.1 million.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 71.11% in 2023 and jumped 744.53% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $76.8 million in 2022, then jumped by 585.21% to $526.5 million in 2023, then slipped by 9.23% to $477.9 million in 2024, then retreated by 11.19% to $424.4 million in 2025, then retreated by 5.67% to $400.4 million in 2026.
• Per Business Quant, the three latest MLTX Liabilities and Shareholders Equity figures stand at $400.4 million (Q1 2026), $424.4 million (Q4 2025), and $414.3 million (Q3 2025).